International Journal of Medical and Pharmaceutical Research
2022, Volume-3, Issue-1 : 38-42 doi: 10.5281/zenodo.16892382
Original Article
Clinical Outcomes of Pectoralis Major Myocutaneous Flap in Head and Neck Reconstruction: A Prospective Study
 ,
Published
May 30, 2022
Abstract

Background: Reconstruction following head and neck cancer surgery remains a major challenge. Although microvascular free flaps are considered the gold standard, resource limitations and technical expertise often make pedicled flaps, particularly the pectoralis major myocutaneous (PMMC) flap, the preferred option in many centers.

Objective: This study aimed to evaluate the outcomes, complications, and reliability of PMMC flap reconstruction in patients with head and neck cancers.

Methods: A prospective observational study was conducted at a tertiary care teaching hospital. Fifty patients with advanced head and neck malignancies requiring composite resections underwent reconstruction using PMMC flap. Patient demographics, tumor characteristics, surgical details, and postoperative outcomes were analyzed.

Results: Among 50 patients (36 males, 14 females; mean age: 54.3 years), oral cavity cancers were most common (72%), followed by oropharyngeal (14%), hypopharyngeal (8%), and laryngeal tumors (6%). PMMC flap was used for mucosal defect coverage in 40 patients, cutaneous coverage in 6, and combined defects in 4 patients. Flap-related complications occurred in 14 patients (28%), including minor partial necrosis (8%), major partial necrosis (4%), wound dehiscence (10%), and fistula formation (6%). No total flap loss was observed. Non-flap-related complications included hematoma (6%) and surgical site infection (12%).

Conclusion: PMMC flap remains a reliable and versatile reconstructive option in head and neck cancer surgery, particularly in resource-limited settings. Despite a moderate complication rate, flap survival was excellent, supporting its continued role as a workhorse flap in head and neck reconstruction.

Recommended Articles
Loading Image...
Volume-3, Issue-1
Citations
2207 Views
190 Downloads
Share this article
License
Copyright (c) International Journal of Medical and Pharmaceutical Research
pdf Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All papers should be submitted electronically. All submitted manuscripts must be original work that is not under submission at another journal or under consideration for publication in another form, such as a monograph or chapter of a book. Authors of submitted papers are obligated not to submit their paper for publication elsewhere until an editorial decision is rendered on their submission. Further, authors of accepted papers are prohibited from publishing the results in other publications that appear before the paper is published in the Journal unless they receive approval for doing so from the Editor-In-Chief.
IJMPR open access articles are licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. This license lets the audience to give appropriate credit, provide a link to the license, and indicate if changes were made and if they remix, transform, or build upon the material, they must distribute contributions under the same license as the original.
Logo
International Journal of Medical and Pharmaceutical Research
About Us
The International Journal of Medical and Pharmaceutical Research (IJMPR) is an EMBASE (Elsevier)–indexed, open-access journal for high-quality medical, pharmaceutical, and clinical research.
Follow Us
© Copyright IJMPR | All Rights Reserved